TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02821910
Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
Study: NCT02024646
Drug: 140 mg brodalumab
Normalized name: brodalumab 140 MG/ML
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 140 mg brodalumab administered via subcutaneous injection.
Study: NCT02821910
Drug: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
Study: NCT01807702
Drug: 13C-Pyruvate 13C-lactate and dichloroacetate
Normalized name: 13C-urea
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
Study: NCT03277079
Drug: statin + ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination of two drugs
Study: NCT03277079
Drug: statin + ezetimibe + Nutraceuticals
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination of two grus plus nutraceuticals
Study: NCT00137813
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
Study: NCT00137813
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
Study: NCT02546765
Drug: IV propofol & placebo
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
Study: NCT02546765
Drug: IV dexmedetomidine & placebo
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
Study: NCT02385188
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: topical 5% imiquimod cream 3 times a week for 16 weeks.
Study: NCT02385188
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02385188
Drug: lidocaine in Vaseline ointment
Normalized name: petrolatum Topical Ointment [Vaseline]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04218123
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily oral intake 37.5 mg
Study: NCT00396747
Drug: Infliximab, methylprednisolone, methotrexate
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00396747
Drug: Methotrexate + Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04387825
Drug: ADSVF application in the right hand
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
Study: NCT02064920
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg donepezil hydrochloride capsule.
Study: NCT00660283
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles.
Study: NCT02064920
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg donepezil hydrochloride capsule.
Study: NCT00579436
Drug: omega-3 fatty acid
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g of omega-3 fatty acid daily by mouth for 12 weeks.
Study: NCT04679545
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A water-soluble sublingual tablet containing 20 mg of CBD.
Study: NCT01614938
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
Study: NCT01614938
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
Study: NCT01614938
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
Study: NCT01614938
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
Study: NCT02312882
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib 5 mg tablet taken by mouth twice a day.
Study: NCT03498001
Drug: GLP-1 agonists
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
Study: NCT01147016
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by physician, standard of care.
Study: NCT01612702
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 10 mg intravenous administration
Study: NCT01016821
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
Study: NCT03791918
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study: NCT03791918
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg intravenously every 2 weeks
Study: NCT01889238
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg administered as four soft gelatin capsules orally once daily
Study: NCT01271933
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: controlled release tablet; 165-495 mg/day; given once daily
Study: NCT02059187
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
Study: NCT00481273
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Physician's discretion
Study: NCT05345236
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal (IVT) injection
Study: NCT01090713
Drug: lisdexamfetamine
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral; 20-70mg/day
Study: NCT01772537
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous anesthetic
Study: NCT01772537
Drug: isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02170311
Drug: Z-213
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01390233
Drug: Prepidil Gel
Normalized name: dinoprostone Vaginal Gel [Prepidil]
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-induction cervical ripening using dinoprostone gel in the vagina.
Study: NCT03769766
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take medication one 500 mg pill of BCM-95 taken twice daily
Study: NCT01031550
Drug: isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
Study: NCT01031550
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard of care
Study: NCT00190944
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01877915
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Study: NCT01384643
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
Study: NCT01740492
Drug: Ketamine 0.15mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
Study: NCT01740492
Drug: Ketamine 0.3mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
Study: NCT01148797
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00542451
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every week for 12 weeks
Study: NCT00542451
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
Study: NCT00272753
Drug: budesonide/formoterol Turbuhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00272753
Drug: formoterol Turbuhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00272753
Drug: salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04309474
Drug: Elezanumab
Normalized name: Elezanumab
DrugBank: Elezanumab (DB15240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT03659851
Drug: Levosimendan 2.5 MG/ML Injectable Solution
Normalized name: levosimendan 2.5 MG/ML Injectable Solution
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVAD implantation
Study: NCT00014027
Drug: Docosahexaenoic acid (DHA)
Normalized name: Docosahexaenoic Acid (DHA)
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00014027
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02717754
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
Study: NCT00679055
Drug: MK-0736
Normalized name: MK-0736
DrugBank: MK-0736 (DB15209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
Study: NCT02920424
Drug: JNJ-56022473
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
Study: NCT02094430
Drug: biological: human fibrinogen concentrate
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02331030
Drug: Ropivacaine 0.5% 20ml
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anaesthetic solution administered for supraclavicular block
Study: NCT02331030
Drug: Ropivacaine 0.5% 10ml
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anaesthetic solution administered for pecs II block
Study: NCT03101579
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Study: NCT03101579
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Study: NCT03101579
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
Study: NCT00528879
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
Study: NCT00528879
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
Study: NCT03598452
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
Study: NCT05602935
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, intravenously, d1
Study: NCT05602935
Drug: SOX
Normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
Study: NCT00307619
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03891576
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Study: NCT00644605
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
Study: NCT00644605
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
Study: NCT00644605
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
Study: NCT02122211
Drug: Betaine supplement
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00618631
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00618631
Drug: Carfentanil
Normalized name: Carfentanil
DrugBank: Carfentanil (DB01535)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04846218
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04846218
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01873703
Drug: pracinostat
Normalized name: Pracinostat
DrugBank: Pracinostat (DB05223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histone deacetylase inhibitor (HDACi)
Study: NCT01873703
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
Study: NCT00672204
Drug: Raptiva
Normalized name: Raptiva
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
Study: NCT00672204
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
Study: NCT00672204
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg on days -2, and -1 IV
Study: NCT04846218
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01081483
Drug: ABT-072
Normalized name: ABT-072
DrugBank: ABT-072 (DB15156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description for more information
Study: NCT00210860
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00274144
Drug: telmisartan 40 mg
Normalized name: telmisartan 40 MG
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01269788
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Study: NCT02934269
Drug: CC-90006
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02787226
Drug: Liposomal Bupivacaine Infiltration
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
Study: NCT01850303
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01850303
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00878449
Drug: etoposide/cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
Study: NCT02930109
Drug: PTX-200
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
Study: NCT02930109
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
Study: NCT03364985
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Forxiga®
Study: NCT02624518
Drug: 68Ga-RM2
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging with PET/MRI
Study: NCT01481831
Drug: Palonosetron Hydrochloride
Normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
Study: NCT01481831
Drug: Palonosetron Hydrochloride
Normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.